Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and ...

生物制药公司Gossamer Bio (NASDAQ: GOSS )在发布好于预期的第四季度业绩报告并更新其肺动脉高压药物候选者seralutinib的进展后，股价上涨5.4%。 公司第四季度每股亏损0.15美元，优于分析师预期的每股亏损0.17美元。营收达到934万美元，超过了702万美元的市场预期。

英为财情Investing.com - Gossamer Bio (NASDAQ: GOSS)星期四发布了第一季度的财报，数据显示，公司营收高于分析师的预期，每股收益超出了分析师的预期。 在该公司发布的最新财报中，公司每股收益为$-0.150，总营收为$9.34M，而此前英为财情Investing.com对分析师的调查显示，分析师预期该公司的营收为$7.02M，每股收益为$-0.170. 财报公布 ...

Gossamer Bio ( ($GOSS) ) has released its Q4 earnings. Here is a breakdown of the information Gossamer Bio presented to its investors. Gossamer ...

Cash, cash equivalents and marketable securities as of December 31, 2024, were $294.5 million. As a result, we expect our ...

EDT Gossamer Bio (GOSS) reports Q4 revenue $9.4M, consensus $7.0MLight Up your Portfolio with Spark:Easily identify stocks' risks and ...

Gossamer Bio (GOSS) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.21 per share a year ago. These figures are ...

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial ...

Gossamer Bio (GOSS) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.21 per share a year ago. These figures are ...

SAN DIEGO - Gossamer Bio, Inc. (NASDAQ: GOSS) saw its shares climb 5.4% after the biopharmaceutical company reported better-than-expected fourth quarter results and provided updates on its pulmonary ...

SAN DIEGO (AP) — SAN DIEGO (AP) — Gossamer Bio Inc. (GOSS) on Thursday reported a loss of $33 million in its fourth quarter. On a per-share basis, the San Diego-based company said it had a loss of 15 ...